![Martin Parschalk](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Martin Parschalk
Director/Miembro de la Junta en Heartbeat.bio AG .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Oliver Szolar | M | - |
Heartbeat.bio AG
![]() Heartbeat.bio AG Miscellaneous Commercial ServicesCommercial Services HeartBeat.bio AG is an Austrian company that specializes in developing a high-throughput human organoid screening platform for cardiac drug discovery. HeartBeat.bio is based in Vienna, AT, at the Biocenter. The company's technology platform is based on self-organizing, scalable cardiac organoids that replicate human heart physiology, allowing for modeling of various diseases such as drug-induced and genetic cardiomyopathies, myocardial infarction, heart remodeling, and regeneration. The company was founded in 2021 by a team with extensive experience in organoid research, drug discovery, and business development. Michael Krebs has been the CEO since incorporation. | - |
Michael Krebs | M | - |
Heartbeat.bio AG
![]() Heartbeat.bio AG Miscellaneous Commercial ServicesCommercial Services HeartBeat.bio AG is an Austrian company that specializes in developing a high-throughput human organoid screening platform for cardiac drug discovery. HeartBeat.bio is based in Vienna, AT, at the Biocenter. The company's technology platform is based on self-organizing, scalable cardiac organoids that replicate human heart physiology, allowing for modeling of various diseases such as drug-induced and genetic cardiomyopathies, myocardial infarction, heart remodeling, and regeneration. The company was founded in 2021 by a team with extensive experience in organoid research, drug discovery, and business development. Michael Krebs has been the CEO since incorporation. | - |
Pablo Hofbauer | M | - |
Heartbeat.bio AG
![]() Heartbeat.bio AG Miscellaneous Commercial ServicesCommercial Services HeartBeat.bio AG is an Austrian company that specializes in developing a high-throughput human organoid screening platform for cardiac drug discovery. HeartBeat.bio is based in Vienna, AT, at the Biocenter. The company's technology platform is based on self-organizing, scalable cardiac organoids that replicate human heart physiology, allowing for modeling of various diseases such as drug-induced and genetic cardiomyopathies, myocardial infarction, heart remodeling, and regeneration. The company was founded in 2021 by a team with extensive experience in organoid research, drug discovery, and business development. Michael Krebs has been the CEO since incorporation. | - |
Sasha Mendjan | M | - |
Heartbeat.bio AG
![]() Heartbeat.bio AG Miscellaneous Commercial ServicesCommercial Services HeartBeat.bio AG is an Austrian company that specializes in developing a high-throughput human organoid screening platform for cardiac drug discovery. HeartBeat.bio is based in Vienna, AT, at the Biocenter. The company's technology platform is based on self-organizing, scalable cardiac organoids that replicate human heart physiology, allowing for modeling of various diseases such as drug-induced and genetic cardiomyopathies, myocardial infarction, heart remodeling, and regeneration. The company was founded in 2021 by a team with extensive experience in organoid research, drug discovery, and business development. Michael Krebs has been the CEO since incorporation. | - |
Thomas Streimelweger | M | 65 |
Heartbeat.bio AG
![]() Heartbeat.bio AG Miscellaneous Commercial ServicesCommercial Services HeartBeat.bio AG is an Austrian company that specializes in developing a high-throughput human organoid screening platform for cardiac drug discovery. HeartBeat.bio is based in Vienna, AT, at the Biocenter. The company's technology platform is based on self-organizing, scalable cardiac organoids that replicate human heart physiology, allowing for modeling of various diseases such as drug-induced and genetic cardiomyopathies, myocardial infarction, heart remodeling, and regeneration. The company was founded in 2021 by a team with extensive experience in organoid research, drug discovery, and business development. Michael Krebs has been the CEO since incorporation. | - |
Gráfico relacional
Relaciones con varias empresas
Estadísticas
País | Relaciones | % del total |
---|---|---|
Austria | 5 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Martin Parschalk
- Red Personal